Gabapentin Capsule
Product Images NDC 71205-532

6 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Gabapentin 01)

Chemical Structure (Gabapentin 01)
Chemical structure diagram of Gabapentin, a human prescription drug. The image shows the molecular layout with a cyclohexane ring attached to an amino group and a carboxylic acid group, indicating its chemical composition.*
FDA Label Image

Figure 1 (Gabapentin 02)

Figure 1 (Gabapentin 02)
Line graph depicting mean pain score over eight weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score from 0 to 10, with Gabapentin showing a decreasing trend in pain score compared to placebo.*
FDA Label Image

Figure 2 (Gabapentin 03)

Figure 2 (Gabapentin 03)
A line graph displaying mean pain score over a period of 7 weeks comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks (baseline to week 7), with a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows the mean pain score from 0 to 10, indicating pain score decreases more with Gabapentin doses compared to placebo.*
FDA Label Image

Figure 3 (Gabapentin 04)

Figure 3 (Gabapentin 04)
Bar chart showing the proportion of responders with at least 50% reduction in pain score at endpoint from two controlled PHN studies. Study 1 compares placebo (PBO) at 12% with Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance indicated for differences.*
FDA Label Image

Figure 4 (Gabapentin 05)

Figure 4 (Gabapentin 05)
A scatter plot comparing difference percentages against daily doses (mg) of Gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose in mg, ranging from 600 to 1800 mg, while the y-axis shows the difference percentage ranging from 2% to 22%. Different symbols denote each study group's data points.*
FDA Label Image

71205-532-90 (223a9216 6e07 49b9 8faf Bb4e529a6ae5 00)

71205-532-90 (223a9216 6e07 49b9 8faf Bb4e529a6ae5 00)
Gabapentin 300 mg capsules packaging label by Proficient Rx LP showing the product contains 90 capsules. The label includes NDC 71205-532-90 and specifies the capsules are size 1 hard gelatin with opaque yellow caps and bodies imprinted with 'SG' and '180' in black ink. Manufacturer is ScieGen Pharmaceuticals, Inc. with storage instructions at 20°-25°C (68°-77°F). Several barcode and QR codes are present along with lot and expiration placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.